PUBLISHER: The Business Research Company | PRODUCT CODE: 1674053
PUBLISHER: The Business Research Company | PRODUCT CODE: 1674053
A veterinary vaccine is a biological preparation designed to stimulate the immune response of an animal, aiming to reduce animal suffering, prevent the transmission of microorganisms within the animal population, and enhance the immune strength of animals for improved health. Additionally, veterinary vaccines play a crucial role in preventing the transmission of diseases from animals to humans.
Various types of veterinary vaccines include live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccine variants. Inactivated vaccines, distinct from live attenuated vaccines, consist of dead or inactivated viruses and bacteria. The diseases targeted by these vaccines encompass anaplasmosis, canine parvovirus, foot and mouth disease, Newcastle disease, distemper disease, influenza, and porcine reproductive and respiratory syndrome. The application areas for veterinary vaccines extend to both livestock vaccines and companion animal vaccines.
The veterinary vaccines research report is one of a series of new reports from The Business Research Company that provides veterinary vaccines statistics, including veterinary vaccines industry global market size, regional shares, competitors with veterinary vaccines share, detailed veterinary vaccines segments, market trends and opportunities, and any further data you may need to thrive in the veterinary vaccines industry. The veterinary vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The veterinary vaccines market size has grown strongly in recent years. It will grow from $13.56 billion in 2024 to $14.52 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to emerging markets growth, increased pet spending, increased disease prevalence, increased outbreak of poultry diseases, and rising incidence of zoonotic diseases.
The veterinary vaccines market size is expected to see strong growth in the next few years. It will grow to $19.4 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to economic growth, increasing penetration of pet insurance, rise in pet ownership, increase in government initiatives, and growing awareness about animal health. Major trends in the forecast period include investing in the development of nanoparticles, increasing the production of subunit and virus-like particle-based vaccines, production of vaccines like parvovirus, distemper, and adenovirus to provide the mandatory and regular vaccination schedule of pet owners, increasing investment in technological advancements, increasing investment on toxoid vaccines, focus on increasing investment on mRNA vaccines, and strategic collaborations and partnerships.
The veterinary vaccines market is experiencing growth driven by the increasing number of animals afflicted with various diseases, creating a demand for vaccines to prevent and treat these conditions. A report from the Animal and Plant Health Agency highlights 3289 new TB herd incidents detected in England, underscoring the significance of diseases such as bovine tuberculosis in animals. The prevalence of diseases, including chronic ailments such as bovine tuberculosis in cattle, contributes to the heightened need for veterinary vaccines, offering preventive and therapeutic solutions.
The growing demand for animal-derived food products is expected to drive the veterinary vaccine market in the coming years. Animal-derived food products include items such as beef, pork, chicken, fish, milk, cheese, butter, eggs, and other animal-based ingredients commonly used across a wide range of food and beverages. The need for disease prevention in animals, along with regulatory standards and food safety concerns, encourages greater adoption of veterinary vaccines. These vaccines protect animal health, help prevent disease outbreaks, and reassure consumers about the quality and safety of food products. For example, in February 2023, the U.S. Department of Agriculture (USDA) reported that, despite rising prices, consumers on average consumed about 227 pounds of poultry, beef, and pork in 2022-up from 224.9 pounds in 2021. Consequently, the growing demand for animal-derived food products is boosting the veterinary vaccine market.
In the veterinary vaccines market, companies are actively forming strategic partnerships and collaborations to expand into new geographical regions and engage in joint research and development projects. Merck Animal Health, for example, established a four-year strategic alliance with Iowa State University, focusing on innovative solutions in animal health through collaborative efforts in research and development, manufacturing, technology exploration, and business expansion. Such partnerships aim to address animal health challenges globally. MSD Animal Health also entered a strategic partnership with Vinovo, enhancing the vaccination process and improving bird welfare by combining MSD Animal Health's vaccine product line with Vinovo's vaccine delivery system. Additionally, Wageningen bio veterinary research collaborated with Ceva to enhance research on emerging and reemerging diseases for animals.
Key players in the veterinary vaccine market are investing in innovation to maintain a competitive edge. Merck Animal Health, for instance, introduced a new three-in-one swine vaccine named Circumvent CML in June 2023. This vaccine offers protection against Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. Circumvent CML combines multiple antigens and adjuvant systems in a single bottle, simplifying the vaccination process and reducing stress for animals and caretakers.
The regulatory landscape of the veterinary vaccines market is governed by authorities such as the European Medicines Agency and the US Center for Veterinary Biologics. In Europe, veterinary vaccine companies must adhere to specific technical requirements outlined in Directive 2001/82/EC and European Pharmacopoeia (Ph. Eur.). Safety tests are mandatory for approval, involving in vitro titration for activated vaccines and serological tests for inactivated vaccines. Batch standards for inactivated vaccines necessitate a dose double the standard for each batch, while activated vaccines must undergo testing with a batch ten times the standard dose. These regulatory measures ensure the safety and efficacy of veterinary vaccines.
Major companies operating in the veterinary vaccines market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Elanco Animal Health Incorporated, Ceva Sante Animale., Virbac Group, HIPRA, Biogenesis Bago, Kyoritsu Seiyaku Corporation, Phibro Animal Health Corporation, Century Vaccines Limited, Bayer Animal Health, Cadila Vaccines Ltd., Cargill India Pvt. Ltd., China Animal Healthcare Ltd., Jurox Pty Ltd, Nimrod Veterinary Products Ltd., Bimeda, Animalcare, MSD Animal Health, Interfeed, Biotex Plus Ltd., Belfarmacom, IDT Biologika, UCBVET, Lemavet, Syntec, Sauvet, Vetanco, Chemo Argentina, Brouwer, Agrovet Market Animal Health, DBK Pharma S.A.E.
North America was the largest region in the veterinary vaccines market in 2024. Asia-Pacific was the second-largest region in the global veterinary vaccines market analysis. The regions covered in the veterinary vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the veterinary vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
The veterinary vaccines market consists of sales of messenger RNA vaccine, viral vector vaccine, and subunit vaccine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Veterinary Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on veterinary vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for veterinary vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The veterinary vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.